DNAprint Genomics (DNAG)

[worktoplay]

GOINGUP11...Agreed...I see only a few possibilities:

1) Cash to be used to fund ongoing operations...not likely, though because they already have debentures in place for those funds.

2) Cash to in-license one or more additional drugs...possible. Perhaps the Cancer drug referred to in the analyst report whose licensing was contingent on additional financing.

3) Cash to complete an acquisition...possible. Gabriel mentioned potential acquisitions in the forensics and consumer products areas.

4) Cash for who knows what...lol

Whatever it is, IMO, we'll see a PR first thing Monday morning letting us know.

Later,
W2P